Tara Cochrane

Tara Cochrane

Auto-generated profile, based on publicly available information

Tara Cochrane

Department of Haematology Gold Coast University Hospital Gold Coast Queensland Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Leukemia & Lymphoma
Verified
Journal Article
Open access
TCTara Cochrane
Tara Cochrane
AEAlicia Enrico
Alicia Enrico
DGDavid Gomez-Almaguer
David Gomez-Almaguer
EHEvgueniy Hadjiev
Evgueniy Hadjiev
ELEwa Lech-Maranda
Ewa Lech-Maranda
MAMary Ann Anderson
Mary Ann Anderson
Venetoclax, a potent B-cell lymphoma-2 (BCL-2) inhibitor, has demonstrated clinical efficacy in chronic lymphocytic leukemia (CLL). VENICE II is an open-label, single-arm, phase 3b study (NCT02980731) evaluating the impact of venetoclax monotherapy (400 mg once daily) for ≤2 years on health-related quality of life (HRQoL) of patients with relapsed/refractory CLL. The primary endpoint was mean change in the global health status (GHS)/quality of life (QoL) subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) from baseline to Week 48. Overall, 210 patients received ≥1 dose of venetoclax; median treatment duration was 67.4 weeks. The primary endpoint was met with mean improvement of +9.3 points (n = 156, 95% confidence interval 6.1–12.5; p=.004) in GHS/QoL. At Week 48, clinically meaningful improvements were observed for role functioning, fatigue, and insomnia domains of EORTC QLQ-C30, suggesting venetoclax monotherapy has a positive impact on HRQoL. No new safety signals were reported.

24 September 2023 in Internal Medicine Journal
Verified
Journal Article
Open access
MAMary A. Anderson
Mary A. Anderson
RBRory Bennett
Rory Bennett
XBXavier Badoux
Xavier Badoux
GBGiles Best
Giles Best
NCNicole Chia
Nicole Chia
SMStephen P. Mulligan
Stephen P. Mulligan
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The availability of next‐generation sequencing and measurable residual disease assessment by flow cytometry allow for advanced prognostication and response assessments. Novel therapies, including inhibitors of Bruton's tyrosine kinase (BTKi) and B‐cell lymphoma 2 (BCL2) inhibitors, have transformed the treatment landscape for both treatment‐naïve and relapsed/refractory disease, particularly for patients with high‐risk genetic aberrations. Recommendations regarding appropriate supportive management continue to evolve, and special considerations are required for patients with CLL with respect to the global SARS‐CoV‐2 pandemic. The unique funding and treatment environments in Australasia highlight the need for specific local guidance with respect to the investigation and management of CLL. This consensus practice statement was developed by a broadly representative group of ANZ experts in CLL with endorsement by peak haematology bodies, with a view to providing this standardised guidance.

14 March 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
KMKate Manos
Kate Manos
LCLeonid Churilov
Leonid Churilov
AGAndrew Grigg
Andrew Grigg
PCPietro Di Ciaccio
Pietro Di Ciaccio
JWJonathan Wong
Jonathan Wong
MLMasa Lasica
Masa Lasica

1 February 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ZGZhong Goh
Zhong Goh
MLMaya Latimer
Maya Latimer
KLKatharine L. Lewis
Katharine L. Lewis
CCChan Y. Cheah
Chan Y. Cheah
PCPietro Di Ciaccio
Pietro Di Ciaccio
TCTara Cochrane
Tara Cochrane

3 March 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
KLKenneth J. C. Lim
Kenneth J. C. Lim
PCPietro Di Ciaccio
Pietro Di Ciaccio
MPMark N. Polizzotto
Mark N. Polizzotto
SMSam Milliken
Sam Milliken
TCTara Cochrane
Tara Cochrane
MKMatthew Ku
Matthew Ku

11 June 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JBJordan Barr
Jordan Barr
HCHeather Campbell
Heather Campbell
LMLloyd McGuire
Lloyd McGuire
TCTara Cochrane
Tara Cochrane
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.